Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
Last trade$161.89
Day change-$0.895 (-0.55%)
Day range$160.29 – $166.00
Volume388,605
Market cap$10.41B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$10.41B
Price / earnings
—
Price / book
4.97×
Price / sales
12.92×
EV / sales
12.7×
EV / EBITDA
70×
Profitability
Earnings per share
-$0.18
Return on assets
-0.4%
Return on equity
-0.56%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.27×
Current ratio
9.88×
Quick ratio
8.43×
Cash ratio
5.78×
Cash flow
Price / cash flow
80.13×
Price / free cash flow
97.5×
Free cash flow
$106.72M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for RGEN, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$209.31M
$204.13M
$194.26M
$197.91M
$188.81M
$182.37M
$169.17M
$167.55M
Cost of revenue
$98.33M
$94.09M
$85.97M
$94.08M
$88.29M
$89.37M
$77.8M
$128.71M
Gross profit
$110.99M
$110.04M
$108.28M
$103.83M
$100.52M
$93M
$91.37M
$38.84M
Selling, general and administrative
$83.59M
$76.62M
$76.54M
$74.36M
$73.66M
$70.91M
$70.71M
$60.47M
Research and development
$14.44M
$14.42M
$14.46M
$13.12M
$14.18M
$13.97M
$12.11M
$11.68M
Total operating expenses
$140.53M
$96.06M
$92.34M
$85.96M
$83.69M
$79.1M
$84.79M
$75.34M
Operating income
-$29.55M
$13.98M
$15.94M
$17.87M
$16.83M
$13.9M
$6.58M
-$36.5M
Interest expense
-$5.71M
-$5.66M
-$5.58M
-$4.25M
-$5.41M
-$5.35M
-$5.25M
-$4.03M
Income before taxes
-$26.81M
$14.15M
$1.77M
$19.11M
$17.11M
$18.22M
$7.94M
-$38.61M
Income taxes
$11.62M
$9.15M
-$6.56M
$5.83M
$2.2M
$3.35M
$2.11M
-$4.74M
Net income
-$38.43M
$5.01M
$8.33M
$13.29M
$14.91M
$14.87M
$5.83M
-$33.87M
Net income attributable to common shareholders
-$38.43M
$5.01M
$8.33M
$13.29M
$14.91M
$14.87M
$5.83M
-$33.87M
EBITDA
$32.79M
$38.06M
$37.05M
$38.31M
$37.9M
$28.2M
$27.26M
-$18.13M
Basic earnings per share
-$0.68
$0.09
$0.15
$0.24
$0.27
$0.26
$0.10
-$0.60
Diluted earnings per share
-$0.68
$0.09
$0.15
$0.23
$0.26
$0.26
$0.10
-$0.62
Recent news
Company coverage with links to the original publishers.
The global continuous bioprocessing technologies market is projected to grow from USD 4.8 billion in 2026 to USD 8.5 billion by 2031, driven by rising biologics demand, regulatory support, and the biopharmaceutical industry's shift from batch to continuous production. Key growth drivers include cost efficiency, improved quality, and faster time to market, though high capital investment and technical complexity remain challenges.
Alkermes announced positive top-line results from a phase I proof-of-concept study of ALKS 7290, an orexin 2 receptor agonist for ADHD treatment. The drug demonstrated dose-dependent, clinically meaningful improvements in ADHD symptoms with median AISRS score reductions of 14-19 points and was well tolerated with no serious adverse effects. Phase II studies are ongoing with data expected in 2027.
The global bioprocess automation market is projected to grow from USD 8.6 billion in 2025 to USD 22.2 billion by 2033, expanding at a CAGR of 12.8%. Growth is driven by rising demand for biologics, advances in AI and robotics, and pressure to improve manufacturing efficiency and regulatory compliance. Automation technologies enhance throughput, consistency, and cost-effectiveness while reducing errors and production time.
Novartis announced positive results from late-stage REMODEL-1/-2 studies showing remibrutinib, a BTK inhibitor, significantly reduced annualized relapse rates versus Aubagio in relapsing multiple sclerosis patients. The drug also reduced inflammatory brain lesions with a favorable safety profile. Novartis plans global regulatory filings and will present data at MSToronto2026. Shares gained 6% on the news.
Jazz Pharmaceuticals missed Q2 2026 EPS expectations ($5.71 vs. $6.04 estimate) due to $77 million in acquired IPR&D expenses, but beat revenue estimates at $1.21 billion. The company raised full-year 2026 revenue guidance to $4.60-$4.75 billion, driven by strong performance in its sleep franchise (Xywav up 13%), epilepsy business (Epidiolex up 16%), and oncology portfolio (up 32%). Despite the positive outlook, shares have underperformed the S&P 500 by 6.9% since the earnings report.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.